MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

108.96 -1.53

Overview

Share price change

24h

Current

Min

108.08

Max

111.99

Key metrics

By Trading Economics

Income

15M

-59M

Sales

2.7M

121M

Profit margin

-48.914

Employees

712

EBITDA

14M

-57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+55.33% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-179M

5.3B

Previous open

110.49

Previous close

108.96

News Sentiment

By Acuity

50%

50%

174 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jul 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 Jul 2025, 17:28 UTC

Major Market Movers

SharpLink Gaming Gains on Ethereum Purchase

11 Jul 2025, 16:57 UTC

Earnings

BASF Cuts Outlook on Global Economy Uncertainty

11 Jul 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 Jul 2025, 19:46 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 Jul 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 Jul 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 Jul 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 Jul 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 Jul 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 Jul 2025, 16:42 UTC

Earnings

BASF Cuts Outlook on Global Economic Uncertainty

11 Jul 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 Jul 2025, 16:05 UTC

Earnings

BASF Will Publish Half-Year Results on July 30

11 Jul 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 Jul 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 Jul 2025, 16:03 UTC

Earnings

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 Jul 2025, 16:02 UTC

Earnings

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 Jul 2025, 16:01 UTC

Earnings

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 Jul 2025, 16:00 UTC

Earnings

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 Jul 2025, 15:59 UTC

Earnings

BASF Cuts 2025 Earnings View

11 Jul 2025, 15:58 UTC

Earnings

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 Jul 2025, 15:57 UTC

Earnings

BASF 2Q EBIT Before Special Items EUR810M

11 Jul 2025, 15:54 UTC

Earnings

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 Jul 2025, 15:54 UTC

Earnings

BASF 2Q Sales Fell 2.1% on Year

11 Jul 2025, 15:53 UTC

Earnings

BASF 2Q Sales EUR15.77B

11 Jul 2025, 15:52 UTC

Earnings

BASF: This Was in Line With Consensus Estimates

11 Jul 2025, 15:52 UTC

Earnings

BASF 2Q Ebitda Before Special Items EUR1.77B

11 Jul 2025, 15:49 UTC

Earnings

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 Jul 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

55.33% upside

12 Months Forecast

Average 172 USD  55.33%

High 210 USD

Low 108 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

174 / 376 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.